LONDON, U.K., April 9, 2021 (LifeSiteNews) — An official review in the U.K. has found that evidence supporting the efficacy and safety of puberty blocking and cross-sex hormone drugs is of “very low certainty,” not reliable, and could be subject to conflicts of interest in favor of the drugs.
Last year, the National Health Service (NHS) in England called for a review into “gender identity services,” which is being led by Dr. Hilary Cass OBE, former president of the Royal College of Paediatrics and Child Health, and hence dubbed the Cass Review.
As part of the independent review, the National Institute for Health and Care Excellence (NICE) is also taking an active role, and has now released two reviews regarding puberty blocking drugs and cross sex hormones.
Puberty blockers
The first review examined a total of nine studies into “gonadotrophin releasing hormone (GnRH) analogues,” or puberty blockers, as well as cross-sex hormones. These examined the use of the drugs in comparison to other non-medical interventions offered to children who suffered from gender dysphoria.
Among other areas, NICE observed the effect of such drugs on children’s mental health, the psychosocial impact, the effect on bone density, cognitive development, “gender dysphoria,” and safety
The remainder of this article is available in its entirety at LifeSite News
The views expressed in this news alert by the author do not directly represent that of The Official Street Preachers or its editors